DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

Lupus is a condition often shrouded in mystery. Presenting with a huge range of symptoms, it’s tricky to diagnose, tough to ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...

A woman who spent nine months in hospital needing 'three amputations' feels like she finally has her life back - after getting a bionic leg. Emilia Lindquist, 27, was diagnosed with lupus - an ...

Aurinia Pharmaceuticals Inc. (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus ...

showing significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus. Dapirolizumab pegol met its primary endpoint, demonstrating ...